SGLT2 inhibitors

Dapagliflozin - Empagliflozin - Ertugliflozin      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

diabetes type 2

dapagliflozin
Yang, 2015      NCTdapagliflozin -
Nauck, 2011      NCTdapagliflozindlipizide add on metformin -
Ferrannini (MB102013), 2010        NCTdapagliflozinplaceboLow risk of bias -
Komoroski (MB102007), 2009      NCTdapagliflozinplaceboExploratory -
List (MB102008), 2009        NCTdapagliflozinplaceboExploratory -
KOhan      NCTdapagliflozinplaceboLow risk of bias -
Kohan      NCTdapagliflozinplacebo -
Kohan      NCTdapagliflozinplacebo -
Kaku, 2014      NCTdapagliflozinplacebo -
Wilding (MB102009), 2009        NCTdapagliflozinplacebo (add on insulin)Low risk of bias -
Wilding, 2012              NCTdapagliflozinplacebo (add on insulin) -
Mathieu, 2015      NCTdapagliflozinplacebo (add on MET + SAXA) -
Bailey (MB102014), 2010          NCTdapagliflozinplacebo (add on MET)Low risk of bias -
Bolinder, 2012          NCTdapagliflozinplacebo (add on MET) -
Schumm-Draeger , 2015      NCTdapagliflozinplacebo (add on MET) -
Matthaei, 2015      NCTdapagliflozinplacebo (add on MET+SU) -
Rosenstock, 2012        NCTdapagliflozinplacebo (add on TZD) -
MB102035    NCTdapagliflozinplacebo (on top standard treatment) -
Cefalu, 2015        NCTdapagliflozinplacebo (on top standard treatment) -
Leiter, 2016      NCTdapagliflozinplacebo (on top standard treatment) -
MB102073    NCTdapagliflozinplacebo (on top standard treatment) -
Weber      NCTdapagliflozinplacebo (on top standard treatment) -
MB102061    NCTdapagliflozinplacebo add on DPP-4 -
Rosenstock, 2015      NCTdapagliflozinSaxagliptin (add on MET) -
Kohan      NCTdapagliflozin + merformindapagliflozin -
Strojek, 2011          NCTdapagliflozin + Glimepirideglimepiride -
MB102034, 2016      NCTdapagliflozin + merforminmetformin or dapa -
empagliflozin
Kadowaki, 2013   empagliflozin -
Kadowaki , 2014     empagliflozin -
Ridderstrale, 2014        NCTempagliflozinGlimepiride + MET -
DeFronzo, 2015        NCTempagliflozinlinagliptin (add-on MET) -
Lewin, 2015      NCTempagliflozinlinagliptin (monotherapy) -
EMPA-REG OUTCOME    NCTempagliflozinplacebo -
Barnett, 2014      NCTempagliflozinplacebo -
Ferrannini, 2013      NCTempagliflozinplacebo -
EMPA-REG MONO (Roden) vs placebo, 2013      NCTempagliflozinplacebo -
Kadowaki, 2015      NCTempagliflozinplacebo -
EMPA-REG PIO (Kovacs), 2013      NCTempagliflozinplacebo (add on MET+/-PIO) -
Rosenstock DOUBLON ???, 2013   empagliflozinplacebo (add-on INS) -
Rosenstock (1245.49), 2014      NCTempagliflozinplacebo (add-on INS+/-MET) -
Rosenstock, 2013      NCTempagliflozinplacebo (add-on MET) -
Ross, 2015     empagliflozinplacebo (add-on MET) -
EMPA-REG MET (Haring), 2014      NCTempagliflozinplacebo (add-on MET) -
Araki, 2015      NCTempagliflozinplacebo (add-on standard treatment) -